Eric Bjerkholt Sells 7,287 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 7,287 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the transaction, the chief financial officer directly owned 49,788 shares of the company’s stock, valued at approximately $4,579,500.24. The trade was a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, January 26th, Eric Bjerkholt sold 1,053 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total value of $101,288.07.
• On Thursday, January 22nd, Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $132,621.93.

Mirum Pharmaceuticals Stock Down 5.1%

Shares of NASDAQ:MIRM opened at $91.66 on Thursday. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $109.28. The firm has a market capitalization of $5.53 billion, a P/E ratio of -190.95 and a beta of 0.52. The stock has a 50 day moving average price of $96.32 and a 200-day moving average price of $81.08. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter in the previous year, the business earned $1.00 EPS. The company’s revenue for the quarter was up 49.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MIRM has been the topic of a number of recent research reports. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $110.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 28th. Morgan Stanley boosted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum announced completion of enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases — a material clinical milestone that keeps the program on track; topline readout is expected in Q4 2026 and could materially re‑rate the stock if positive. Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap
• Neutral Sentiment: Institutional investors and analysts show continued interest: several large institutions increased positions in recent quarters and multiple sell‑side firms have raised price targets (consensus remains a “Moderate Buy” with a mid‑teens upside to consensus targets). This supports underlying demand but is not an immediate catalyst. MarketBeat Mirum Stock Page
• Negative Sentiment: Several insiders sold sizable blocks of stock on March 16 (CEO Christopher Peetz sold 40,985 shares for ~$3.77M; COO Peter Radovich sold 16,515 shares; CFO Eric Bjerkholt, SVP Jolanda Howe and others also sold) — all at an average price near $91.98. Large, clustered insider sales can be interpreted as profit‑taking and often weigh on sentiment even when executives retain meaningful stakes. SEC filing for the CEO sale: Peetz Form 4 — SVP sale coverage: InsiderTrades SVP Sale

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIRM. Comerica Bank increased its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC boosted its stake in Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Mirum Pharmaceuticals by 7.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares during the last quarter. Caxton Associates LLP purchased a new stake in Mirum Pharmaceuticals during the 1st quarter valued at about $217,000. Finally, Empowered Funds LLC increased its stake in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.